Lesion severity and hypercholesterolemia determine long-term prognosis of vasospastic angina treated with calcium

Masakazu Yamagishi1, Kenichi Ito, Hiroshi Tsutsui

  • 1Division of Cardiovascular Medicine, National Cardiovascular Center, Suita, Japan. myamagi@hsp.ncvc.go.jp

Insights

Significant coronary artery stenosis is the primary predictor of poor outcomes in vasospastic angina patients treated with calcium channel blockers. High LDL-C also contributes to cardiac events, especially in patients without significant stenosis.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Clinical Prognosis

Background:

  • Medically treated vasospastic angina (VSA) patients generally have good outcomes.
  • Limited data exist on the prognostic impact of underlying lesion severity and hyperlipidemia in VSA.
  • Understanding these factors is crucial for refining long-term VSA management.

Purpose of the Study:

  • To assess the relationship between long-term outcomes of VSA and influencing prognostic factors.
  • To investigate the role of coronary artery stenosis (CAS) and hyperlipidemia in VSA prognosis.

Main Methods:

  • A cohort of 256 VSA patients treated with calcium channel antagonists were followed for 13.6 years.
  • Cardiac events included cardiac death, acute myocardial infarction, and unstable angina.
  • Cox analysis and Kaplan-Meier survival analysis were used to identify predictors of event-free survival.

Main Results:

  • Significant CAS (>50%) was an independent predictor of poorer event-free survival (HR=2.84, p<0.0001).
  • In patients without significant CAS, high low-density lipoprotein-cholesterol (LDL-C) was an independent predictor of poorer event-free survival (HR=3.89, p=0.02).
  • Patients with significant CAS had significantly lower event-free survival than those without (p<0.0001).

Conclusions:

  • Significant coronary artery stenosis is the most critical factor for long-term prognosis in VSA patients on calcium channel antagonists.
  • High LDL-C may contribute to cardiac events, particularly in VSA patients without significant coronary artery stenosis.
  • These findings highlight the importance of assessing lesion severity and managing lipid levels in VSA patients.

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...